Using neem tree extracts as a starting point, scientists have created several kinds of nanozymes and tested them for ...

Early research shows that editing expanding trinucleotide repeats halts the lengthening process that causes neurological ...

Proteins represent 95% of drug targets designed to combat disease, according to Yvonne Tan, PhD, from Nuclera.

T therapies is an expensive business. The fundamental problem is that CAR-T production is not a good fit for centralized manufacturing.

A scientist says he has shown that it’s possible to produce a large amount of virus-like particles using a fully scalable process.

Single-use continuous bioprocessing can reduce mAb production costs and shorten time-to-market compared to batch processing.

Wacker and Expression Manufacturing want to offer clients with an end-to-end, optimized solution for viral vector development and production.

Rocket Pharmaceuticals acknowledged the death of a patient in a pivotal trial assessing its Danon disease gene therapy candidate RP-A501, a study that the FDA has placed on clinical hold.

The first systematic genome-wide association study for pseudogout has identified two genes strongly associated with disease progression.

How CD4+ T cells respond to Chikungunya virus may trigger long-lasting joint pain, mimicking autoimmune disease long after infection clears.

Using deep learning techniques, scientists generated an artificial protein that successfully changes its shape to bind and ...

Typically, the goal of ALS treatments is to slow the disease or halt progression. But new data from the antisense oligonucleotide (ASO) jacifusen for FUS-ALS show that two patients went beyond the ...